Epigenetic Alterations Associated With CCCTC-Binding Factor Deregulation in Prostate Cancer

2011 ◽  
Author(s):  
Sachin Bhusari
2014 ◽  
Vol 47 (1) ◽  
pp. 22-30 ◽  
Author(s):  
Lei Gu ◽  
◽  
Sandra C Frommel ◽  
Christopher C Oakes ◽  
Ronald Simon ◽  
...  

2010 ◽  
Vol 9 (6) ◽  
pp. 576
Author(s):  
T. Kalogeropoulos ◽  
E. Dimitriadis ◽  
V. Klapsas ◽  
S. Sotiriou ◽  
E. Koutsiaris ◽  
...  

2011 ◽  
Vol 10 (2) ◽  
pp. 171
Author(s):  
T.C. Stadler ◽  
A. Jung ◽  
B. Schlenker ◽  
A.L. Boulesteix ◽  
C. Bernau ◽  
...  

2020 ◽  
Vol 4 (1) ◽  
Author(s):  
Xuanrong Chen ◽  
Qianwang Ma ◽  
Zhiqun Shang ◽  
Yuanjie Niu

AbstractAbnormal activity of oncogenic and tumor-suppressor signaling pathways contributes to cancer and cancer risk in humans. Transcriptional dysregulation of these pathways is commonly associated with tumorigenesis and the development of cancer. Genetic and epigenetic alterations may mediate dysregulated transcriptional activity. One of the most important epigenetic alternations is the non-coding regulatory element, which includes both enhancers and super-enhancers (SEs). SEs, characterized as large clusters of enhancers with aberrant high levels of transcription factor binding, have been considered as key drivers of gene expression in controlling and maintaining cancer cell identity. In cancer cells, oncogenes acquire SEs and the cancer phenotype relies on these abnormal transcription programs driven by SEs, which leads to cancer cells often becoming addicted to the SEs-related transcription programs, including prostate cancer. Here, we summarize recent findings of SEs and SEs-related gene regulation in prostate cancer and review the potential pharmacological inhibitors in basic research and clinical trials.


2007 ◽  
Vol 6 (2) ◽  
pp. 191
Author(s):  
M. Hering ◽  
U. Schmidt ◽  
S. Füssel ◽  
A. Lohse ◽  
K. Robel ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document